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Two laws aiming to provide a new legal framework to promote regenerative medicine, while ensuring the ef-
ficacy and safety of the treatments, came into effect in Japan on November 25, 2014. The scope of these laws
is briefly described here.Introduction
Prior to 2014, there were no statute-
based regulations in Japan providing
oversight for regenerative medicine,
including stem cell therapies, other than
pharmaceutical regulations that covered
cellular and tissue-based products.
During this time, Japan was unable to
safeguard against patients, including
foreigners, seeking unproven stem cell
therapy (so-called medical tourism), and
as a result, some patients seeking treat-
ment experienced severe and even life-
threatening problems (Editorial, 2013).
On the other hand, regenerative medi-
cine, including the use of induced
pluripotent stem cells (iPSCs), is an
important component of healthcare
strategy in Japan, whose population
has the one of the highest propor-
tions of aged individuals in the world
and is expected to increase. For these
reasons, a new regulatory framework
was required for regenerative medicine,
and to meet this need, two laws known
as the ‘‘The Act on the Safety of
Regenerative Medicine’’ (http://www.
hourei.mhlw.go.jp/cgi-bin/t_docframe2.
cgi?MODE=hourei&DMODE=SEARCH&
SMODE=NORMAL&KEYWORD=%8d%
c4%90%b6%88%e3%97%c3%93%99&
EFSNO=229&FILE=FIRST&POS=0&HITSU=
306) and the ‘‘Pharmaceuticals, Medical
Devices and Other Therapeutic Prod-
ucts Act’’ (http://www.hourei.mhlw.go.jp/
cgi-bin/t_docframe.cgi?MODE=hourei&
DMODE=CONTENTS&SMODE=NORMAL&
KEYWORD=&EFSNO=638) came into ef-
fect on November 25, 2014. Here,
we provide a description of the new
regulations and approval process, and
we discuss how the new regulations
address deficiencies in the previous
system.350 Cell Stem Cell 16, April 2, 2015 ª2015 ElThe Act on the Safety of
Regenerative Medicine
The Act on the Safety of Regenerative
Medicine regulates medical profes-
sionals’ practices and clinical studies
related to regenerative medicine, which
had previously been under the jurisdiction
of the Medical Practitioners’ Act and the
Medical Care Act. The new Act sets out
regulations not only for ‘‘regenerative
medicine’’ to reconstruct or repair human
structures and functions, but also for cell-
based therapies such as cancer immuno-
therapy. Prior to the new regulations,
clinical studies involving human stem
cell therapies were conducted according
to guidelines known as ‘‘the human stem
cell clinical research guidelines,’’ which
were not legally binding. However, the
new Act sets out legal regulations not
only for research, but also for the daily
practice of cell therapy without approved
regenerative medical products.
Medical technologies that use items
such as stromal vascular fraction (SVF),
which have recently become an issue in
the United States, will be regulated in
Japan under the Act (Dolgin, 2014).
This law divides regenerative medicine
into three categories, depending on the
potential risks (Table 1). For example,
the level of risk associated with medical
treatment that uses SVF would be
considered as either medium or low.
Any plan to use regenerative medicine
has to be submitted to the Ministry of
Health, Labour and Welfare (MHLW)
regardless of which of the three risk cat-
egories the treatment falls into. Addition-
ally, a medical institution that wishes to
offer regenerative medicine must solicit
opinions from a certified special commit-
tee or a certified committee for regener-
ative medicine about their regenerativesevier Inc.medicine provision plan before they can
submit the plan to the MHLW (Figure S1).
These committees are considered as ful-
filling the legally stipulated accreditation
criteria by the MHLW. After obtaining
the committee’s opinion, whether it rec-
ommends approval or not, the medical
institution can submit their regenerative
medicine provision plan, accompanied
by the opinion of the committee, to the
MHLW. Furthermore, after the initial sub-
mission is filed, the medical institution is
obligated to report adverse events and
annual details about the level of imple-
mentation, such as the name of the pro-
vided regenerative medicine, number of
patients treated, and evaluation of the
treatment, to the MHLW and the commit-
tee. The MHLW will periodically publish a
summary based on these reports to
assure transparency of medical institu-
tions that provide regenerative medicine.
The availability of this data is important,
because the full picture of regenerative
medicine (including cell therapy) activ-
ities, which have been performed without
restriction to date, has been unclear; the
real status of these therapies is expected
to become apparent as a result of the
Act. Although there have been sugges-
tions that self-reporting is not enough,
the Act will enable the MHLW to get a
comprehensive picture of the regenera-
tive medicine that is actually being prac-
ticed for the first time, and it is therefore
an important step in securing the medical
safety of the Japanese population.
A high profile example of a study that
would be affected by the new Act is the
world’s first transplantation of retinal
pigmentation epithelial cells developed
from human iPSCs, which was performed
as a clinical study by Dr. Takahashi’s
group in September 2014 (Reardon and
Table 1. Classification of Regenerative Medical Technologies According to Risk
Category Example of Cells Used for Regenerative Medicine Example of Treatments
Class I (high risk) iPSCs, ESCs, cells into which a gene is introduced,
xenogeneic cells, allogeneic cells
transplantation of retinal pigment epithelium cells
derived from autologous iPSCs, ex vivo gene therapy
Class II (medium risk) autologous somatic stem cells autologous mesenchymal stem cell infusion therapy
for liver cirrhosis
Class III (low risk) autologous somatic cells cancer immunotherapy
Regenerative medical technologies are divided into three classes depending on the potential risk to human health.
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studies using human iPSCs such as this
will be placed in the high-risk medical
technology category. Under the Act,
studies falling into the highest risk cate-
gory of the three classes require review
at the national level. After submission of a
provision plan to provide regenerative
medicine that is classified as high-risk to
the MHLW, the MHLW can postpone im-
plementation of the proposed plan for a
maximum of 90 days. According to the
Act, the MHLWmust review the appropri-
ateness of the plan by consulting the
Health Science Council within the 90-day
period. The duration of the review is
shorter than similar procedures in the pre-
vious system to ensure consistency in the
review process under human stem cell
clinical research guidelines.
The Act on the Safety of Regenerative
Medicine stipulates usage ofGMP-type fa-
cilities/equipment and quality control re-
quirements for cell processing facilities
that manufacture cells for clinical study
and medical treatment. These require-
ments are designed to ensure safety and
are concerned with the facilities and
equipment, as well as manufacturing and
quality control. If processed cells are
manufactured in a medical institution, noti-
fication to the MLHW is necessary,
declaring that the cell processing facility
complies with the aforementioned require-
ments. Ifprocessedcells aremanufactured
locally by an entity such as a company
that is not part of a medical institution,
the entity must obtain a manufacturing
license from the MHLW, then receive an
inspection by the Pharmaceuticals
Medical Devices Agency (PMDA) to check
adherence to the requirements. If pro-
cessed cells are manufactured outside
the country, the manufacturer is subject
to the same requirements as local Japa-
nese manufacturers.
In short, theActseeks topromote regen-
erative medicine by facilitating clinicalstudies, even those involving companies,
while ensuring safety. After this phase of
clinical studies, clinical trials are regulated
by the Pharmaceuticals, Medical Devices
and Other Therapeutic Products Act.
Pharmaceuticals, Medical Devices
andOther Therapeutic Products Act
The Pharmaceutical Affairs Law was
revised and renamed the Pharmaceuti-
cals, Medical Devices and Other Thera-
peutic Products Act (PMD Act). This Act
provides the option of a new pathway
to obtain conditional and time-limited
approval for ‘‘regenerative medical
products,’’ which takes into account
the high degree of quality variability of
cells in the products and therapies that
fall under this classification (Figure 1)
(Hara et al., 2014). The approval review
process will adopt a 9-month target
for regulatory review time (http://www.
pmda.go.jp/files/000155330.pdf), follow-
ing expansion of the PMDA (from751 peo-
ple to 1,065 people) (http://www.mhlw.
go.jp/kouseiroudoushou/shokanhoujin/
dokuritsu/shiryou02/dl/kyouka01.pdf). As
a result, the review period for products un-
der the PMD Act will be shorter than that
of already approved products in Japan.
However, to obtain conditional and time-
limited approval, exploratory clinical trials
are required to predict reasonable likeli-
hood of clinical benefit (for example, by
using a surrogate endpoint); this is consis-
tent with the US Food and Drug Adminis-
tration’s (FDA’s) accelerated approval
scheme for serious or life-threatening ill-
nesses (http://www.fda.gov/ForPatients/
Approvals/Fast/ucm405447.htm). The
European Agency is putting forward
the concept of adaptive licensing as a
flexible approach to product approval,
which is prospectively planned, and
where uncertainty is reduced through the
collection of post-approval data on the
medicine’s use in patients (Eichler et al.,
2012; http://www.ema.europa.eu/ema/Cell Stem Ceindex.jsp?curl=pages/regulation/general/
general_content_000601.jsp). In The In-
ternational Conference on Harmonisation
of Technical Requirements for Registra-
tion of Pharmaceuticals for Human
Use (ICH) member regions, regulatory
agencies have tried to respond to pa-
tient/medical needs by developing an
early access scheme to new therapies,
weighing the safety and efficacy of
the products in relation to the product
life cycle (Table S1). From this perspec-
tive, conditional and time-limited approval
is quite in linewith global regulatory trends
to resolve unmet medical needs. Over-
seas enterprises may also participate in
the new Japanese regulatory system.
A confirmatory clinical study and fol-
lowup patient safety measures, including
restrictions on clinical institutions that
may use the treatment, must follow
the conditional and time-limited approval,
in preparation for a further approval
process within a maximum period of
7 years. In order to ensure that products
with unconfirmed effectiveness do not
remain on the market, the new regula-
tion gives MHLW/PMDA a clear legal
authority to withdraw approval during
the second approval process. The scope
of regenerative medical products is
considered to be mainly products satis-
fying unmet medical needs (including
orphan indications and serious or life-
threatening illnesses), which may also
require a surgical procedure in some
cases. Because of these circumstances,
conventional drug regulation may not
necessarily be applicable and amore flex-
ible approach to safety and efficacy eval-
uation is called for. The sponsor is also
encouraged to engage in regulatory
consultation, since the design of fur-
ther clinical studies and how best to
demonstrate effectiveness may depend
on the individual product, in terms of the
indicated use, population, and mode of
action and medical environment. At thell 16, April 2, 2015 ª2015 Elsevier Inc. 351
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Figure 1. New Approval Process for Regenerative Medical Products
Under the traditional approval process, long-term data collection and evaluation in clinical trials for regen-
erative medical products are needed, and so a new, separate approval process has been created. If an
exploratory clinical trial predicts likely clinical benefit, the regenerative medical product will be given con-
ditional, time-limited approval.
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Forumsame time, the MHLW and PMDA will
establish a public patient registry system
to support more accurate studies on post-
marketing safety and efficacy in patients
treated with regenerative medical prod-
ucts (http://www.mhlw.go.jp/stf/shingi/
0000050197.html).
Regenerative medical products that are
approved under the PMD Act will not be
subject to the Act on the Safety of Regen-
erative Medicine (except for off-label use)
insofar as they are being used within the
conditions of their approval. The concrete
reimbursement policy for the products
granted conditional and time-limited352 Cell Stem Cell 16, April 2, 2015 ª2015 Elapproval is being worked out at the Cen-
tral Social Insurance Medical Council,
following the Council’s discussion in
November 2014 to open the door to reim-
bursement and pricing for these products.
These two laws represent an attempt
by Japan to promptly deliver regenerative
medicine to patients while ensuring the ef-
ficacy and safety of application of regen-
erative medicine.
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